Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes
OBJECTIVE:--To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS--A total of 50 adult type 1 diabetic subjects with a baseline BMI [>/=]27 kg/m² were randomly assigned in a double-blind fashion to take...
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2005-07, Vol.28 (7), p.1562-1567 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1567 |
|---|---|
| container_issue | 7 |
| container_start_page | 1562 |
| container_title | Diabetes care |
| container_volume | 28 |
| creator | Strowig, Suzanne M Raskin, Philip |
| description | OBJECTIVE:--To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS--A total of 50 adult type 1 diabetic subjects with a baseline BMI [>/=]27 kg/m² were randomly assigned in a double-blind fashion to take insulin and placebo (n = 25) or insulin and rosiglitazone 4 mg twice daily (n = 25) for a period of 8 months. Insulin regimen and dosage were modified in all subjects to achieve near-normal glycemic control. RESULTS:--Both groups experienced a significant reduction in HbA[subscript 1c] (A1C) level (rosiglitazone: 7.9 ± 1.3 to 6.9 ± 0.7%, P < 0.0001; placebo: 7.7 ± 0.8 to 7.0 ± 0.9%, P = 0.002) and a significant increase in weight (rosiglitazone: 97.2 ± 11.8 to 100.6 ± 16.0 kg, P = 0.008; placebo: 96.4 ± 12.2 to 99.1 ± 15.0, P = 0.016). Baseline measures of BMI (P = 0.001), total daily insulin dose (P = 0.002), total cholesterol (P = 0.005), HDL cholesterol (P = 0.00l), and LDL cholesterol (P = 0.02) were predictors of improvement in A1C level only in the group treated with rosiglitazone. Total daily insulin dose increased in subjects taking placebo (74.0 ± 33.8 to 82.0 ± 48.9 units, P < 0.05 baseline vs. week 32), but it decreased slightly in subjects taking rosiglitazone (77.5 ± 28.6 to 75.3 ± 33.1 units). Both systolic blood pressure (137.4 ± 15.6 vs. 128.8 ± 14.8 mmHg, baseline vs. week 32, P < 0.02) and diastolic blood pressure (87.2 ± 9.4 vs. 79.4 ± 7.2 mmHg, P < 0.0001) improved in the group treated with rosiglitazone. The total incidence of hypoglycemia did not differ between groups. CONCLUSIONS:--Rosiglitazone in combination with insulin resulted in improved glycemic control and blood pressure without an increase in insulin requirements, compared with insulin- and placebo-treated subjects, whose improved glycemic control required an 11% increase in insulin dose. Weight gain and hypoglycemia were similar in both groups at the end of the study. The greatest effect of rosiglitazone occurred in subjects with more pronounced markers of insulin resistance. |
| doi_str_mv | 10.2337/diacare.28.7.1562 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_gale_infotracgeneralonefile_A134209966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A134209966</galeid><sourcerecordid>A134209966</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-613f1ae91b4885ce1424f31d33740a00c77d8650539c544748d311223c8f14533</originalsourceid><addsrcrecordid>eNptkUtr3DAUhUVpaaZpf0A3rSm0i4JdXT0saRmm6QMCgSahS6GRJY8Gjz2R7Ib011eDDYEyaCEQ3zn36B6E3gKuCKXiSxOMNdFVRFaiAl6TZ2gFivKScyafoxUGpkquFDlDr1LaYYwZk_IlOgOuJKUYVmh96b2zYzH44teQQtuF0fwdelcMfXH9x8UHF9rtWNxMm13GUvE7jNvi9vHgCii-BrNxo0uv0QtvuuTeLPc5uvt2ebv-UV5df_-5vrgqLad8LGugHoxTsMkhuHXACPMUmvwThg3GVohG1hxzqixnTDDZUABCqJUeGKf0HH2afQ9xuJ9cGvU-JOu6zvRumJKuhRKCKJzBD_-Bu2GKfc6msx2mktQsQ-UMtaZzOvR-GKOxretdNF3egA_5-QIoI1ipus58dYLPp3H7YE8KYBbYOKQUndeHGPYmPmrA-tifXvrTRGqhj_1lzbsl-bTZu-ZJsRSWgY8LYJI1nY-mtyE9cbUCoehxBZ9nbpv7ewh5SLO0dXLq-xn2ZtCmjdnw7obkaRgwrrHi9B95qbg2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223038264</pqid></control><display><type>article</type><title>Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Strowig, Suzanne M ; Raskin, Philip</creator><creatorcontrib>Strowig, Suzanne M ; Raskin, Philip</creatorcontrib><description>OBJECTIVE:--To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS--A total of 50 adult type 1 diabetic subjects with a baseline BMI [>/=]27 kg/m² were randomly assigned in a double-blind fashion to take insulin and placebo (n = 25) or insulin and rosiglitazone 4 mg twice daily (n = 25) for a period of 8 months. Insulin regimen and dosage were modified in all subjects to achieve near-normal glycemic control. RESULTS:--Both groups experienced a significant reduction in HbA[subscript 1c] (A1C) level (rosiglitazone: 7.9 ± 1.3 to 6.9 ± 0.7%, P < 0.0001; placebo: 7.7 ± 0.8 to 7.0 ± 0.9%, P = 0.002) and a significant increase in weight (rosiglitazone: 97.2 ± 11.8 to 100.6 ± 16.0 kg, P = 0.008; placebo: 96.4 ± 12.2 to 99.1 ± 15.0, P = 0.016). Baseline measures of BMI (P = 0.001), total daily insulin dose (P = 0.002), total cholesterol (P = 0.005), HDL cholesterol (P = 0.00l), and LDL cholesterol (P = 0.02) were predictors of improvement in A1C level only in the group treated with rosiglitazone. Total daily insulin dose increased in subjects taking placebo (74.0 ± 33.8 to 82.0 ± 48.9 units, P < 0.05 baseline vs. week 32), but it decreased slightly in subjects taking rosiglitazone (77.5 ± 28.6 to 75.3 ± 33.1 units). Both systolic blood pressure (137.4 ± 15.6 vs. 128.8 ± 14.8 mmHg, baseline vs. week 32, P < 0.02) and diastolic blood pressure (87.2 ± 9.4 vs. 79.4 ± 7.2 mmHg, P < 0.0001) improved in the group treated with rosiglitazone. The total incidence of hypoglycemia did not differ between groups. CONCLUSIONS:--Rosiglitazone in combination with insulin resulted in improved glycemic control and blood pressure without an increase in insulin requirements, compared with insulin- and placebo-treated subjects, whose improved glycemic control required an 11% increase in insulin dose. Weight gain and hypoglycemia were similar in both groups at the end of the study. The greatest effect of rosiglitazone occurred in subjects with more pronounced markers of insulin resistance.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/diacare.28.7.1562</identifier><identifier>PMID: 15983301</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Adult ; Biological and medical sciences ; Blood Glucose - metabolism ; blood pressure ; Body Mass Index ; Body Size ; C-Peptide - blood ; cholesterol ; Diabetes ; Diabetes Mellitus, Type 1 - complications ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes. Impaired glucose tolerance ; dose response ; Double-Blind Method ; Drug therapy ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Ethnic Groups ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; Glycated Hemoglobin A - analysis ; glycemic control ; Humans ; hypoglycemia ; Hypoglycemic agents ; Hypoglycemic Agents - therapeutic use ; insulin ; Insulin - therapeutic use ; insulin resistance ; insulin-dependent diabetes mellitus ; Male ; Medical sciences ; Metabolic diseases ; Metabolism ; Obesity ; Obesity - complications ; Obesity - drug therapy ; overweight ; Overweight persons ; Placebos ; Prescription drugs ; Rosiglitazone ; Rosiglitazone maleate ; Side effects ; Thiazolidinediones - therapeutic use ; Type 1 diabetes ; Weight Gain</subject><ispartof>Diabetes care, 2005-07, Vol.28 (7), p.1562-1567</ispartof><rights>2005 INIST-CNRS</rights><rights>COPYRIGHT 2005 American Diabetes Association</rights><rights>Copyright American Diabetes Association Jul 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-613f1ae91b4885ce1424f31d33740a00c77d8650539c544748d311223c8f14533</citedby><cites>FETCH-LOGICAL-c535t-613f1ae91b4885ce1424f31d33740a00c77d8650539c544748d311223c8f14533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16917930$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15983301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strowig, Suzanne M</creatorcontrib><creatorcontrib>Raskin, Philip</creatorcontrib><title>Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>OBJECTIVE:--To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS--A total of 50 adult type 1 diabetic subjects with a baseline BMI [>/=]27 kg/m² were randomly assigned in a double-blind fashion to take insulin and placebo (n = 25) or insulin and rosiglitazone 4 mg twice daily (n = 25) for a period of 8 months. Insulin regimen and dosage were modified in all subjects to achieve near-normal glycemic control. RESULTS:--Both groups experienced a significant reduction in HbA[subscript 1c] (A1C) level (rosiglitazone: 7.9 ± 1.3 to 6.9 ± 0.7%, P < 0.0001; placebo: 7.7 ± 0.8 to 7.0 ± 0.9%, P = 0.002) and a significant increase in weight (rosiglitazone: 97.2 ± 11.8 to 100.6 ± 16.0 kg, P = 0.008; placebo: 96.4 ± 12.2 to 99.1 ± 15.0, P = 0.016). Baseline measures of BMI (P = 0.001), total daily insulin dose (P = 0.002), total cholesterol (P = 0.005), HDL cholesterol (P = 0.00l), and LDL cholesterol (P = 0.02) were predictors of improvement in A1C level only in the group treated with rosiglitazone. Total daily insulin dose increased in subjects taking placebo (74.0 ± 33.8 to 82.0 ± 48.9 units, P < 0.05 baseline vs. week 32), but it decreased slightly in subjects taking rosiglitazone (77.5 ± 28.6 to 75.3 ± 33.1 units). Both systolic blood pressure (137.4 ± 15.6 vs. 128.8 ± 14.8 mmHg, baseline vs. week 32, P < 0.02) and diastolic blood pressure (87.2 ± 9.4 vs. 79.4 ± 7.2 mmHg, P < 0.0001) improved in the group treated with rosiglitazone. The total incidence of hypoglycemia did not differ between groups. CONCLUSIONS:--Rosiglitazone in combination with insulin resulted in improved glycemic control and blood pressure without an increase in insulin requirements, compared with insulin- and placebo-treated subjects, whose improved glycemic control required an 11% increase in insulin dose. Weight gain and hypoglycemia were similar in both groups at the end of the study. The greatest effect of rosiglitazone occurred in subjects with more pronounced markers of insulin resistance.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - metabolism</subject><subject>blood pressure</subject><subject>Body Mass Index</subject><subject>Body Size</subject><subject>C-Peptide - blood</subject><subject>cholesterol</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - complications</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>dose response</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Ethnic Groups</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>glycemic control</subject><subject>Humans</subject><subject>hypoglycemia</subject><subject>Hypoglycemic agents</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>insulin</subject><subject>Insulin - therapeutic use</subject><subject>insulin resistance</subject><subject>insulin-dependent diabetes mellitus</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Metabolism</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>overweight</subject><subject>Overweight persons</subject><subject>Placebos</subject><subject>Prescription drugs</subject><subject>Rosiglitazone</subject><subject>Rosiglitazone maleate</subject><subject>Side effects</subject><subject>Thiazolidinediones - therapeutic use</subject><subject>Type 1 diabetes</subject><subject>Weight Gain</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkUtr3DAUhUVpaaZpf0A3rSm0i4JdXT0saRmm6QMCgSahS6GRJY8Gjz2R7Ib011eDDYEyaCEQ3zn36B6E3gKuCKXiSxOMNdFVRFaiAl6TZ2gFivKScyafoxUGpkquFDlDr1LaYYwZk_IlOgOuJKUYVmh96b2zYzH44teQQtuF0fwdelcMfXH9x8UHF9rtWNxMm13GUvE7jNvi9vHgCii-BrNxo0uv0QtvuuTeLPc5uvt2ebv-UV5df_-5vrgqLad8LGugHoxTsMkhuHXACPMUmvwThg3GVohG1hxzqixnTDDZUABCqJUeGKf0HH2afQ9xuJ9cGvU-JOu6zvRumJKuhRKCKJzBD_-Bu2GKfc6msx2mktQsQ-UMtaZzOvR-GKOxretdNF3egA_5-QIoI1ipus58dYLPp3H7YE8KYBbYOKQUndeHGPYmPmrA-tifXvrTRGqhj_1lzbsl-bTZu-ZJsRSWgY8LYJI1nY-mtyE9cbUCoehxBZ9nbpv7ewh5SLO0dXLq-xn2ZtCmjdnw7obkaRgwrrHi9B95qbg2</recordid><startdate>20050701</startdate><enddate>20050701</enddate><creator>Strowig, Suzanne M</creator><creator>Raskin, Philip</creator><general>American Diabetes Association</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0K</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20050701</creationdate><title>Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes</title><author>Strowig, Suzanne M ; Raskin, Philip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-613f1ae91b4885ce1424f31d33740a00c77d8650539c544748d311223c8f14533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - metabolism</topic><topic>blood pressure</topic><topic>Body Mass Index</topic><topic>Body Size</topic><topic>C-Peptide - blood</topic><topic>cholesterol</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - complications</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>dose response</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Ethnic Groups</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>glycemic control</topic><topic>Humans</topic><topic>hypoglycemia</topic><topic>Hypoglycemic agents</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>insulin</topic><topic>Insulin - therapeutic use</topic><topic>insulin resistance</topic><topic>insulin-dependent diabetes mellitus</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Metabolism</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>overweight</topic><topic>Overweight persons</topic><topic>Placebos</topic><topic>Prescription drugs</topic><topic>Rosiglitazone</topic><topic>Rosiglitazone maleate</topic><topic>Side effects</topic><topic>Thiazolidinediones - therapeutic use</topic><topic>Type 1 diabetes</topic><topic>Weight Gain</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strowig, Suzanne M</creatorcontrib><creatorcontrib>Raskin, Philip</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Agricultural Science Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strowig, Suzanne M</au><au>Raskin, Philip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2005-07-01</date><risdate>2005</risdate><volume>28</volume><issue>7</issue><spage>1562</spage><epage>1567</epage><pages>1562-1567</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>OBJECTIVE:--To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS--A total of 50 adult type 1 diabetic subjects with a baseline BMI [>/=]27 kg/m² were randomly assigned in a double-blind fashion to take insulin and placebo (n = 25) or insulin and rosiglitazone 4 mg twice daily (n = 25) for a period of 8 months. Insulin regimen and dosage were modified in all subjects to achieve near-normal glycemic control. RESULTS:--Both groups experienced a significant reduction in HbA[subscript 1c] (A1C) level (rosiglitazone: 7.9 ± 1.3 to 6.9 ± 0.7%, P < 0.0001; placebo: 7.7 ± 0.8 to 7.0 ± 0.9%, P = 0.002) and a significant increase in weight (rosiglitazone: 97.2 ± 11.8 to 100.6 ± 16.0 kg, P = 0.008; placebo: 96.4 ± 12.2 to 99.1 ± 15.0, P = 0.016). Baseline measures of BMI (P = 0.001), total daily insulin dose (P = 0.002), total cholesterol (P = 0.005), HDL cholesterol (P = 0.00l), and LDL cholesterol (P = 0.02) were predictors of improvement in A1C level only in the group treated with rosiglitazone. Total daily insulin dose increased in subjects taking placebo (74.0 ± 33.8 to 82.0 ± 48.9 units, P < 0.05 baseline vs. week 32), but it decreased slightly in subjects taking rosiglitazone (77.5 ± 28.6 to 75.3 ± 33.1 units). Both systolic blood pressure (137.4 ± 15.6 vs. 128.8 ± 14.8 mmHg, baseline vs. week 32, P < 0.02) and diastolic blood pressure (87.2 ± 9.4 vs. 79.4 ± 7.2 mmHg, P < 0.0001) improved in the group treated with rosiglitazone. The total incidence of hypoglycemia did not differ between groups. CONCLUSIONS:--Rosiglitazone in combination with insulin resulted in improved glycemic control and blood pressure without an increase in insulin requirements, compared with insulin- and placebo-treated subjects, whose improved glycemic control required an 11% increase in insulin dose. Weight gain and hypoglycemia were similar in both groups at the end of the study. The greatest effect of rosiglitazone occurred in subjects with more pronounced markers of insulin resistance.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>15983301</pmid><doi>10.2337/diacare.28.7.1562</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2005-07, Vol.28 (7), p.1562-1567 |
| issn | 0149-5992 1935-5548 |
| language | eng |
| recordid | cdi_gale_infotracgeneralonefile_A134209966 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Biological and medical sciences Blood Glucose - metabolism blood pressure Body Mass Index Body Size C-Peptide - blood cholesterol Diabetes Diabetes Mellitus, Type 1 - complications Diabetes Mellitus, Type 1 - drug therapy Diabetes. Impaired glucose tolerance dose response Double-Blind Method Drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Ethnic Groups Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Glycated Hemoglobin A - analysis glycemic control Humans hypoglycemia Hypoglycemic agents Hypoglycemic Agents - therapeutic use insulin Insulin - therapeutic use insulin resistance insulin-dependent diabetes mellitus Male Medical sciences Metabolic diseases Metabolism Obesity Obesity - complications Obesity - drug therapy overweight Overweight persons Placebos Prescription drugs Rosiglitazone Rosiglitazone maleate Side effects Thiazolidinediones - therapeutic use Type 1 diabetes Weight Gain |
| title | Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T00%3A03%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Rosiglitazone%20on%20Overweight%20Subjects%20With%20Type%201%20Diabetes&rft.jtitle=Diabetes%20care&rft.au=Strowig,%20Suzanne%20M&rft.date=2005-07-01&rft.volume=28&rft.issue=7&rft.spage=1562&rft.epage=1567&rft.pages=1562-1567&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/diacare.28.7.1562&rft_dat=%3Cgale_proqu%3EA134209966%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223038264&rft_id=info:pmid/15983301&rft_galeid=A134209966&rfr_iscdi=true |